Sun Pharmaceuticals Industries Ltd Share Price (SUNPHARMA)

Motilal Oswal Reiterates Buy Rating for Sun Pharma - 24 Apr, 2024

Motilal Oswal has reiterated its Buy rating for Sun Pharmaceuticals Industries Ltd. with a target price of Rs 1,870 per share. The report highlights the company's specialty drug pipeline and expects an overall R&D expenditure increase by 33% YoY in FY24.

Sun Pharma Monitoring Situation in Israel - 20 Apr, 2024

Sun Pharmaceuticals Industries Ltd is monitoring the situation in Israel through its subsidiary, Taro Pharmaceutical, and taking necessary steps to ensure employee safety.

Sun Pharma's Taro Pharmaceutical may face supply chain issues - 19 Apr, 2024

Sun Pharma's subsidiary, Taro Pharmaceutical, based in Israel, could experience supply chain problems. Companies like Sun Pharma Lupin, Torrent, and Divis Labs are likely to be affected due to their significant presence in the MENA region.

Sun Pharma Faces Regulatory Challenges - 18 Apr, 2024

Sun Pharmaceuticals Industries Ltd faces regulatory challenges after its Dadra facility was classified as Official Action Indicated (OAI) by the US FDA. Analysts and investors hold a bearish view on the stock, which may fall up to Rs 1,330 apiece in the rest of the month.

Delhi High Court Upholds Order Against Glenmark Pharmaceuticals - 17 Apr, 2024

The Delhi High Court has upheld its order restraining Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet or any other deceptively similar mark to Sun Pharma's Istamet XR CP until the case is disposed of.

Sun Pharma Shares Decline on Regulatory Concerns - 15 Apr, 2024

Sun Pharma's shares decline due to USFDA issuing an OAI tag to its Mumbai unit, which may impact new launches. Analysts expect limited earnings impact but see a regulatory overhang for the drugmaker.

Sun Pharma Shares Fall After US FDA Classification - 12 Apr, 2024

Sun Pharmaceutical Industries Ltd faced a significant setback when its Dadra facility was classified as Official Action Indicated by the US Food and Drug Administration, leading to a 4% decline in share prices. The company will cooperate with regulators to achieve compliance status.

Sun Pharma's Future Looks Bright Amid Positive Forecasts - 09 Apr, 2024

Indian pharma companies are expected to see significant YoY revenue growth in Q4 FY24. Prabhudas Lilladher maintains its bullish stance on healthcare sector and has picked Sun Pharma as its top pick with a BUY rating and target price of Rs 1,640.

Sun Pharma Drops for Fifth Straight Session - 08 Apr, 2024

Sun Pharmaceuticals Industries Ltd has dropped for a fifth straight session and is quoting at Rs 1602.95, down 0.38% on the day as of 13:19 IST on the NSE. The volume in the stock stood at 5.96 lakh shares today.

Sun Pharma Appoints New CIO - 04 Apr, 2024

Sun Pharmaceuticals Industries Ltd has appointed Dheeraj Sinha as the new Executive Vice President and Chief Information Officer, effective from April 3, 2024. He replaces Anil Rao who resigned for personal reasons.

Sun Pharma Receives High Buy Calls from Analysts - 03 Apr, 2024

Sun Pharmaceutical Industries receives high optimism from analysts due to its strong standing in the global specialty space and robust outlook for its India business. The company's MD, Dilip Shanghvi, is India's richest man. Additionally, Mr. Dheeraj Sinha replaces Mr. Anil Rao as EVP and CIO.

Sun Pharma Hits 52-Week High Amid Positive Outlook - 28 Mar, 2024

Sun Pharmaceuticals Industries Ltd's stock hit a new 52-week high amid a positive outlook for its specialty portfolio. HSBC maintained a buy rating and raised the target price to Rs 1790. The filing of Nidlegy with the EU regulator and FDA approval for alopecia drug 900 deuruxolitinib are key catalysts for future growth.

Sun Pharma Founder Dilip Shanghvi's Wealth Reaches ₹1,64,300 Crore - 27 Mar, 2024

Dilip Shanghvi, the founder of Sun Pharmaceutical Industries, has a wealth of ₹1,64,300 crore. The Mumbai-based company remains a powerhouse in the pharmaceutical industry and continues to grow under his leadership.